



Achieving a better cure for cancer

TEAM

Prof dr. Gerard M.J. Bos

CEO, CMO, founder

Dr Wilfred T.V. Germeraad

CSO, COO, founder

Dr Yvo M.F. Graus

CBO



SUPERVISORY BOARD

Drs Daan van den Noort, MD

Advisor on business development, financing and strategy.

Drs Alexander Vos, MSc, MBA

Advisor on business development, financing and strategy.

SCIENTIFIC ADVISORY BOARD

Prof dr Joachim Aerts

Pulmonologist and Medical Oncologist at the Erasmus Medical Centre in Rotterdam.

Prof dr John Haanen

Internist with emphasis on Medical Oncology in the Antoni van Leeuwenhoek (AVL) as well as investigator at the department immunotherapy of the Dutch Cancer Institute in Amsterdam.

CiMaas is a Biotech company based in Maastricht the Netherlands

A city known for its international collaborations

The problem and our challenge

Current anti-cancer therapies cure about 60% of all patients in the Western world. Therefore, cancer is still a leading cause of death in most industrial countries. Immunotherapy is a promising opportunity to further limit the number of people that succumb from cancer in the future. It is CiMaas' perspective to add valuable years to the lives of people with cancer by making use of the immune system.

New therapeutic concepts as solution to fight cancer

Inspired by nature, CiMaas will bring two aspects of the immune system together to enhance the killing capacity of the system as a whole: inducing anti-cancer capacity by killer cells and strengthen this cell response by the use of antibodies (Figure 1). It will do so for several types of cancer, to start with lung cancer, multiple myeloma and acute myeloid leukemia, diseases with unmet needs. The technologies can be applied to a wide range of other cancers.

- The CiMaas tumor target dendritic cell (DC) vaccination platform generates extremely potent (very high Interleukin-12 [and other cytokines] production) and **patient specific** DCs. Giving an electric pulse, any tumor antigen of choice can be introduced into these DCs. As a result, a much stronger priming of a specific anti-tumor T cell immune response with tumor cell-killing capacity in comparison to current available vaccines is generated. CiMaas will actively explore the **synergy** between marketed immune cell checkpoint inhibitor monoclonal antibodies that enhance the immune response of the patient. Together this will create a powerful anti-cancer platform treatment.
- Natural Killer (NK) cell expansion technology provides the capability for the treatment of cancer using very high numbers of **donor** derived NK cells with a strong potential to kill tumor cells, already proven in pre-clinical models. Since Q3 2019, CiMaas works closely together with KiadisPharma. In addition, CiMaas is developing procedures to further optimize the potency of NK cells.

Investment details

A round realised in 2015-1018

B round foreseen in 2020

For further information please

contact us:

E: info@cimaas.com

Gerard MJ Bos, CEO

T: +31-6-10711914

E: gerardmjbos@cimaas.com

W: www.cimaas.com

Addresses:

Main office

Oxfordlaan 70, 6229 EV Maastricht | P.O. Box 1036, 6201 BA Maastricht, the Netherlands

GMP facility

Brightlands Chemelot Campus
Urmonderbaan 22, Building 6
6167 RD Geleen, the Netherlands

The intelligence of the immune system will survive cancer




Figure 1: The CiMaas vision on engaging the full potential of the immune system in the battle against cancer. A) Patients' own (green) Dendritic cells will activate tumor specific T cells and by taking of the brake of these T cells, by blocking with check-point inhibitors, the T cells will not exhaust. B) Used in another setting, expanded donor NK cells (red) that are highly active by themselves will be targeted to the tumor of a patient (green) and even further activated in the presence of antibodies.

Our team

The CiMaas executive team has expert knowledge and experience in immunology research, clinical oncology, biotech business, regulatory affairs, as well as finance and works with an expert network to realize the company's goals. CiMaas operates as a highly efficient integrated biotech and collaborates with several strategic partners. CiMaas, together with Neuroplast, has since December 2019 its own GMP cleanroom facility in Geleen, the Netherlands, where it produces cells for clinical application in patients.

Generating value for patients and shareholders

CiMaas' technology will make present available technologies (antibodies) more efficacious and the combined treatment more cost-effective and as such creating added value for patients, partners and shareholders. Our technology will be developed and approved likely within 6 years after start of phase I/II trials, creating patient benefit and financial return in a relatively short time frame in this industry. Given the broad applicability of CiMaas' technology for a range of cancers, it represents an enormous (commercial) potential.